NEW YORK, July 12, 2018 (GLOBE NEWSWIRE) -- InMode Ltd., a manufacturer and distributor of medical-aesthetic technology to doctors around the world, is pleased to announce the launch and FDA clearance of the Triton hair removal device. Triton, is the first and only high power laser to offer simultaneous multi-wavelength hair removal firing, allowing concurrent emissions of Alexandrite, Diode and Nd:YAG wavelengths.
With the Triton’s simultaneous multi-wavelength, practitioners are now able to treat a broader range of hair and skin types with a high level of power. Combining the three most popular hair removal wavelengths in one device, practitioners can now achieve safety and efficiency, without compromising results.
The Triton has two hand pieces:
In the past, lasers had to reduce peak power or increase pulse width to reduce the risk for postinflammatory hyperpigmentation (PIH) in darker skin types. Now with the Triton, high power and a blend of wavelengths are optimized make this the ultimate system for hair removal.
According to the American Society of Aesthetic Plastic Surgery 2017 survey, hair removal is the number one sought after energy-based aesthetic procedure in the world.
“Although hair removal may appear to be a commodity that is readily available, it still remains the single most popular device procedure. The Triton is a revolutionary new technology that will provide practitioners with the ability to offer faster, safer, more comfortable procedure, while decreasing the number of treatments. This will lead to an increase in patient satisfaction and practice profitability,” says Shakil Lakhani, President of InMode North America.
About InMode: InMode’s technological advancements are the new standard for aesthetic medicine, specifically in the radio-frequency and laser market. For three decades our R&D team was critical in developing state-of-the-art light, laser and radio-frequency devices, thereby launching and shaping the industry. Our technology continues that legacy in providing superior satisfaction for both the patients and the practitioners. Learn more at www.inmodemd.com.
Nermene Fakhr / Behrman Communications email@example.com / 212.986.7000